| Identification | Back Directory | [Name]
L-Isoleucine, N2-(2-methyl-1-oxopropyl)-L-glutaminyl-L-threonyl-L-leucyl-(αS,3S,6R)-3-amino-6-hydroxy-α-[(1S)-1-methylpropyl]-2-oxo-1-piperidineacetyl-N-methyl-L-tyrosyl-, (6→2)-lactone | [CAS]
1122484-55-2 | [Synonyms]
LM-030
KLK7/ELA2-IN-1
L-Isoleucine, N2-(2-methyl-1-oxopropyl)-L-glutaminyl-L-threonyl-L-leucyl-(αS,3S,6R)-3-amino-6-hydroxy-α-[(1S)-1-methylpropyl]-2-oxo-1-piperidineacetyl-N-methyl-L-tyrosyl-, (6→2)-lactone | [Molecular Formula]
C46H72N8O12 | [MOL File]
1122484-55-2.mol | [Molecular Weight]
929.11 |
| Hazard Information | Back Directory | [Uses]
LM-030 (BPR277) is a potent kallikrein-related peptidase 7 (KLK7) and epidermal elastase 2 (ELA2) inhibitor with IC50s of 6 nM and 55 nM, respectively(Example 4)[1]. LM-030 can be used for the study of Netherton syndrome[2]. | [References]
[1] Philipp Krastel, et al. Cyclic depsipeptides. WO2009024527A1
[2] Evgeniya Petrova, et al. Advances in understanding of Netherton syndrome and therapeutic implications. Expert Opinion on Orphan Drugs. 29 Dec 2020. |
|
|